Published in Nephrol Dial Transplant on September 07, 2004
Study of the association between the donors and recipients angiotensin-converting enzyme insertion/deletion gene polymorphism and the acute renal allograft rejection. J Nephropathol (2015) 0.77
ACE genotype and long-term graft survival after renal transplantation. Nephrol Dial Transplant (2005) 0.75
Prevention of DNA damage in renal transplantation by losartan and enalapril: the role of renin-angiotensin system polymorphisms. Clin Exp Nephrol (2008) 0.75
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Reports of large immunosuppression trials in kidney transplantation: room for improvement. Am J Transplant (2004) 2.40
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation (2009) 2.28
In-vivo interaction of nitric oxide and endothelin. J Hypertens (2004) 2.20
New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. Nat Genet (2012) 1.90
A systematic approach to managing pregnant dialysis patients--the importance of an intensified haemodiafiltration protocol. Nephrol Dial Transplant (2005) 1.87
Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant (2004) 1.77
Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens (2005) 1.73
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol (2002) 1.71
Low birth weight, a risk factor for cardiovascular diseases in later life, is already associated with elevated fetal glycosylated hemoglobin at birth. Circulation (2006) 1.61
Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant (2010) 1.59
Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation (2012) 1.56
Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats. J Hypertens (2004) 1.51
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation. Transplantation (2015) 1.47
Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension (2011) 1.46
Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure. Circ Heart Fail (2009) 1.43
The 'blood group O problem' in kidney transplantation--time to change? Nephrol Dial Transplant (2010) 1.42
The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant (2004) 1.42
Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol (2011) 1.42
Integrating an evidence-based medicine rotation into an internal medicine residency program. Acad Med (2004) 1.41
New evidence for the fetal insulin hypothesis: fetal angiotensinogen M235T polymorphism is associated with birth weight and elevated fetal total glycated hemoglobin at birth. J Hypertens (2010) 1.41
FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes. Transplantation (2004) 1.40
Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care (2005) 1.39
Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation (2005) 1.39
Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation (2008) 1.34
Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 1.25
A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int (2008) 1.24
Age and immune response in organ transplantation. Transplantation (2005) 1.23
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure. J Pathol (2014) 1.22
ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol (2005) 1.21
Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int (2008) 1.17
Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab (2012) 1.15
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens (2010) 1.15
Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant (2005) 1.11
Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells. Ther Drug Monit (2009) 1.11
Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol (2007) 1.10
Long-term outcomes after acute kidney injury. Crit Care Med (2008) 1.09
Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol (2003) 1.09
Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension (2004) 1.08
Old-for-old kidney allocation allows successful expansion of the donor and recipient pool. Am J Transplant (2003) 1.08
Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol (2007) 1.07
Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol (2010) 1.07
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics (2008) 1.07
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One (2011) 1.07
Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J (2013) 1.06
Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J (2002) 1.05
Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant (2004) 1.05
DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res (2012) 1.05
Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology (2002) 1.04
Duration of donor brain death and its influence on kidney graft function. Am J Transplant (2002) 1.04
Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS One (2011) 1.04
Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant (2003) 1.03
The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol (2003) 1.01
Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism. Pharmacogenet Genomics (2009) 1.00
The severity of acute cellular rejection defined by Banff classification is associated with kidney allograft outcomes. Transplantation (2014) 0.99
Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J Hypertens (2014) 0.99
Pregnancy on intensified hemodialysis: fetal surveillance and perinatal outcome. Fetal Diagn Ther (2007) 0.99
Determinants of knowledge gain in evidence-based medicine short courses: an international assessment. Open Med (2010) 0.98
Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet (2010) 0.97
Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant (2013) 0.97
Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int (2008) 0.97
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation (2010) 0.97
Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opin Drug Saf (2014) 0.97
Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther (2004) 0.96
Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl Int (2007) 0.95
MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol (2004) 0.95
Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant (2011) 0.95
NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br J Pharmacol (2006) 0.95
Prematurity is related to high placental cortisol in preeclampsia. Pediatr Res (2009) 0.95
Complement-binding anti-HLA antibodies and kidney transplantation. N Engl J Med (2014) 0.95
ETB receptor deficiency causes salt-sensitive hypertension. J Mol Med (Berl) (2002) 0.95
Use of Neoral C monitoring: a European consensus. Transpl Int (2005) 0.94
Hyperaldosteronism in Klotho-deficient mice. Am J Physiol Renal Physiol (2010) 0.94
Renal elimination of troponin T and troponin I. Clin Chem (2003) 0.94
Renal transplantation in the elderly: surgical complications and outcome with special emphasis on the Eurotransplant Senior Programme. Nephrol Dial Transplant (2008) 0.94
Recognition of critical situations from time series of laboratory results by case-based reasoning. J Am Med Inform Assoc (2002) 0.93
Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. Nephron (2016) 0.93
Age-related penetrance of hereditary atypical hemolytic uremic syndrome. Ann Hum Genet (2011) 0.92
Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther Drug Monit (2007) 0.92
CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am J Pathol (2009) 0.92
Impact of the variability of cyclosporin A trough levels on long-term renal allograft function. Nephrol Dial Transplant (2002) 0.92
Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation (2006) 0.92
Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int (2014) 0.92
FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. J Clin Pharmacol (2005) 0.92
Estimated one-year glomerular filtration rate is the best predictor of long-term graft function following renal transplant. Transplantation (2006) 0.91
Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics (2004) 0.91
Improved diagnosis of early kidney allograft dysfunction by ultrasound with echo enhancer--a new method for the diagnosis of renal perfusion. Nephrol Dial Transplant (2006) 0.91